Neutralizing antibodies (NAbs) are naturally produced by our immune system to combat viral
infections. Clinically, neutralizing antibodies with potent efficacy and high specificity have …

To date, all major modes of monoclonal antibody therapy targeting SARS-CoV-2 have lost
significant efficacy against the latest circulating variants. As SARS-CoV-2 omicron …

Understanding of infection dynamics is important for public health measures against
monkeypox virus (MPXV) infection. Herein, samples from multiple body sites and …

In contrast to other species, cattle possess exceptional antibodies with ultra-long
complementarity-determining regions (ulCDRs) that can consist of 40-70 amino acids. The …

The emergence of novel potentially pandemic pathogens necessitates the rapid
manufacture and deployment of effective, stable, and locally manufacturable vaccines on a …

Background and purpose The pandemic of COVID-19 has highlighted the need for
managing infectious diseases, which spreads by airborne transmission leading to serious …

Almost all the neutralizing antibodies targeting the receptor-binding domain (RBD) of spike
(S) protein show weakened or lost efficacy against severe acute respiratory syndrome …

Broadly neutralizing antibodies have huge potential as novel antiviral therapeutics due to
their ability to recognize highly conserved epitopes that are seldom mutated in viral variants …

Omicron sub-lineage BA. 2 has rapidly surged globally, accounting for over 60% of recent
SARS-CoV-2 infections. Newly acquired RBD mutations and high transmission advantage …

The SARS-COV-2 variants of concern (VOCs) accumulated mutations that confer to the viral
particle a higher infectivity as well as a capacity to escape neutralizing antibodies (NAbs) …